| Year |
Citation |
Score |
| 2023 |
Robb KP, Galipeau J, Shi Y, Schuster M, Martin I, Viswanathan S. Failure to launch commercially-approved mesenchymal stromal cell therapies: what's the path forward? Proceedings of the International Society for Cell & Gene Therapy (ISCT) Annual Meeting Roundtable held in May 2023, Palais des Congrès de Paris, Organized by the ISCT MSC Scientific Committee. Cytotherapy. PMID 37804284 DOI: 10.1016/j.jcyt.2023.09.001 |
0.368 |
|
| 2021 |
Viswanathan S, Ciccocioppo R, Galipeau J, Krampera M, Le Blanc K, Martin I, Moniz K, Nolta J, Phinney DG, Shi Y, Szczepiorkowski ZM, Tarte K, Weiss DJ, Ashford P. Consensus International Council for Commonality in Blood Banking Automation-International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. Cytotherapy. PMID 34116944 DOI: 10.1016/j.jcyt.2021.04.009 |
0.32 |
|
| 2021 |
Galipeau J, Krampera M, Leblanc K, Nolta JA, Phinney DG, Shi Y, Tarte K, Viswanathan S, Martin I. Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition. Cytotherapy. PMID 33714704 DOI: 10.1016/j.jcyt.2020.11.007 |
0.302 |
|
| 2020 |
Khoury M, Rocco PRM, Phinney DG, Krampera M, Martin I, Viswanathan S, Nolta JA, LeBlanc K, Galipeau J, Weiss DJ. Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential. Cytotherapy. PMID 32933835 DOI: 10.1016/J.Jcyt.2020.04.089 |
0.386 |
|
| 2020 |
Robb KP, Rabani R, Marshall W, Mahomed N, Audet J, Gandhi R, Viswanathan S. Culture methods to enhance therapeutic potency of mesenchymal stromal cells for Osteoarthritis Osteoarthritis and Cartilage. 28. DOI: 10.1016/J.Joca.2020.02.805 |
0.384 |
|
| 2020 |
Rabani R, Chan M, Jaskarndip C, Mahomed N, Marshall K, Gandhi R, Viswanathan S. Dual role of IL6 mediated by mesenchymal stromal cell signaling to joint macrophages in osteoarthritis Osteoarthritis and Cartilage. 28. DOI: 10.1016/J.Joca.2020.02.802 |
0.336 |
|
| 2020 |
Rabani R, Chahal J, Mahomed N, Marshall K, Gandhi R, Viswanathan S. Microrna profile of mesenchymal stromal cells: A tool to predict their therapeutic efficacy in osteoarthritis Osteoarthritis and Cartilage. 28. DOI: 10.1016/J.Joca.2020.02.792 |
0.356 |
|
| 2020 |
Chan M, Rabani R, Gandhi R, Tian Y, Gaudet I, Viswanathan S. Rapid 48-hour inflammation-resolving polarization of monocytes/macrophages is feasible at larger scale and shows anabolic effect in human osteoarthritic joint explant model Cytotherapy. 22. DOI: 10.1016/J.Jcyt.2020.03.223 |
0.375 |
|
| 2020 |
Robb K, Rabani R, Audet J, Gandhi R, Viswanathan S. Desirability profiling to rank scalable mesenchymal stromal cell enhancement methods according to multimodal mechanisms Cytotherapy. 22. DOI: 10.1016/J.Jcyt.2020.03.201 |
0.362 |
|
| 2020 |
Rabani R, Chahal J, Mahomed N, Marshall K, Gandhi R, Viswanathan S. Microrna profile of mesenchymal stromal cells: a tool to predict their therapeutic efficasy in osteoarthritis Cytotherapy. 22. DOI: 10.1016/J.Jcyt.2020.03.173 |
0.324 |
|
| 2019 |
Hamilton AM, Cheung WY, Gómez-Aristizábal A, Sharma A, Nakamura S, Chaboureau A, Bhatt S, Rabani R, Kapoor M, Foster PJ, Viswanathan S. Iron nanoparticle-labeled murine mesenchymal stromal cells in an osteoarthritic model persists and suggests anti-inflammatory mechanism of action. Plos One. 14: e0214107. PMID 31794570 DOI: 10.1371/Journal.Pone.0214107 |
0.354 |
|
| 2019 |
Rockel JS, Rabani R, Viswanathan S. Anti-fibrotic mechanisms of exogenously-expanded mesenchymal stromal cells for fibrotic diseases. Seminars in Cell & Developmental Biology. PMID 31757583 DOI: 10.1016/J.Semcdb.2019.10.014 |
0.386 |
|
| 2019 |
Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, Nolta J, Phinney DG, Sensebe L. Mesenchymal stem versus stromal cells: International Society for Cellular Therapy Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. PMID 31526643 DOI: 10.1016/J.Jcyt.2019.08.002 |
0.46 |
|
| 2019 |
Chisholm J, Ruff C, Viswanathan S. Current state of Health Canada regulation for cellular and gene therapy products: potential cures on the horizon. Cytotherapy. PMID 31196821 DOI: 10.1016/J.Jcyt.2019.03.005 |
0.356 |
|
| 2019 |
Bubela T, Boch R, Viswanathan S. Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in Canada. Frontiers in Medicine. 6: 58. PMID 30984761 DOI: 10.3389/Fmed.2019.00058 |
0.332 |
|
| 2019 |
Chahal J, Gómez-Aristizábal A, Shestopaloff K, Bhatt S, Chaboureau A, Fazio A, Chisholm J, Weston A, Chiovitti J, Keating A, Kapoor M, Ogilvie-Harris DJ, Syed KA, Gandhi R, Mahomed NN, ... ... Viswanathan S, et al. Bone Marrow Mesenchymal Stromal Cells in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation. Stem Cells Translational Medicine. PMID 30964245 DOI: 10.1002/Sctm.18-0183 |
0.39 |
|
| 2019 |
Chan MWY, Viswanathan S. Recent progress on developing exogenous monocyte/macrophage-based therapies for inflammatory and degenerative diseases. Cytotherapy. PMID 30871899 DOI: 10.1016/J.Jcyt.2019.02.002 |
0.388 |
|
| 2019 |
Waseem S, Audet J, Viswanathan S. Statistical modeling to optimize the manufacturing process of mesenchymal stromal cells Osteoarthritis and Cartilage. 27. DOI: 10.1016/J.Joca.2019.02.464 |
0.329 |
|
| 2019 |
Rabani R, Yan C, Gómez-Aristizábal A, Viswanathan S. Understanding the dual role of IL6 signaling mediated by mesenchymal stromal cell signaling to joint macrophages in osteoarthritis Osteoarthritis and Cartilage. 27: S429-S430. DOI: 10.1016/J.Joca.2019.02.453 |
0.321 |
|
| 2019 |
Robb K, Gómez-Aristizábal A, Gandhi R, Viswanathan S. A culture engineering strategy to enhance mesenchymal stromal cells for treatment of osteoarthritis Osteoarthritis and Cartilage. 27: S427. DOI: 10.1016/J.Joca.2019.02.447 |
0.347 |
|
| 2019 |
Chan M, Gómez-Aristizábal A, Gandhi R, Marshall W, Mahomed N, Viswanathan S. Ex vivo polarized pro-inflammatory vs. homeostatic monocytes/macrophages elicit differential responses within a human osteoarthritic joint explant model Osteoarthritis and Cartilage. 27: S379-S380. DOI: 10.1016/J.Joca.2019.02.378 |
0.324 |
|
| 2019 |
Cheung W, Gómez-Aristizábal A, Hamilton A, Nakamura S, Chaboureau A, Bhatt S, Sharma A, Kapoor M, Foster P, Viswanathan S. Iron nanoparticle-labeled mesenchymal stromal cells persist and demonstrate anti-inflammatory mechanism of action in an osteoarthritis mouse model Osteoarthritis and Cartilage. 27: S90. DOI: 10.1016/J.Joca.2019.02.128 |
0.318 |
|
| 2019 |
Rabani R, Chan M, Gómez-Aristizábal A, Viswanathan S. Dual role of IL6 mediated by mesenchymal stromal cell signaling to joint macrophages in osteoarthritis Cytotherapy. 21: S15-S16. DOI: 10.1016/J.Jcyt.2019.03.582 |
0.301 |
|
| 2019 |
Robb K, Gómez-Aristizábal A, Gandhi R, Viswanathan S. Culture enhanced mesenchymal stromal cells with increased potency Cytotherapy. 21: S94-S95. DOI: 10.1016/J.Jcyt.2019.03.532 |
0.378 |
|
| 2019 |
Hamilton A, Cheung W, Gómez-Aristizábal A, Nakamura S, Chaboureau A, Bhatt S, Sharma A, Kapoor M, Foster P, Viswanathan S. Iron nanoparticle-labeled mesenchymal stromal cells persist and demonstrate anti-inflammatory mechanism of action in an osteoarthritis mouse model Cytotherapy. 21: S94. DOI: 10.1016/J.Jcyt.2019.03.531 |
0.338 |
|
| 2019 |
Chan M, Gomez-Aristizabal A, Rabani R, Gandhi R, Marshall W, Mahomed N, Viswanathan S. Development of an abbreviated protocol for the polarization and characterization of therapeutic inflammation-resolving monocytes/macrophages Cytotherapy. 21: S93-S94. DOI: 10.1016/J.Jcyt.2019.03.530 |
0.328 |
|
| 2018 |
Robb KP, Fitzgerald JC, Barry F, Viswanathan S. Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency. Cytotherapy. PMID 30528726 DOI: 10.1016/J.Jcyt.2018.10.014 |
0.377 |
|
| 2018 |
Fink C, Gaudet JM, Fox MS, Bhatt S, Viswanathan S, Smith M, Chin J, Foster PJ, Dekaban GA. 19F-perfluorocarbon-labeled human peripheral blood mononuclear cells can be detected in vivo using clinical MRI parameters in a therapeutic cell setting. Scientific Reports. 8: 590. PMID 29330541 DOI: 10.1038/S41598-017-19031-0 |
0.316 |
|
| 2018 |
Chaboureau A, Bhatt S, Gómez-Aristizábal A, Chisholm J, Amanda W, Fazio A, Kapoor M, Keating A, Ogilvie-Harris D, Mahomed N, Gandhi R, Marshall W, Syed K, Naraghi A, Chahal J, ... Viswanathan S, et al. Potential anti-inflammatory mechanism of action of mesenchymal stromal cells in osteoarthritis patients results in overall improvement in pain and symptoms Osteoarthritis and Cartilage. 26: S295. DOI: 10.1016/J.Joca.2018.02.592 |
0.322 |
|
| 2018 |
Chan M, Gómez-Aristizábal A, Gandhi R, Viswanathan S. Differential responses to ex vivo polarized monocytes/macrophages in a human osteoarthritis joint explant co-culture Osteoarthritis and Cartilage. 26: S127-S128. DOI: 10.1016/J.Joca.2018.02.278 |
0.319 |
|
| 2018 |
Chan M, Gomez-Aristizabal A, Gandhi R, Marshall W, Mahomed N, Viswanathan S. Ex vivo polarized monocytes/macrophages modulate inflammatory and catabolic responses in a human joint explant model of osteoarthritis Cytotherapy. 20: S114. DOI: 10.1016/J.Jcyt.2018.02.339 |
0.301 |
|
| 2018 |
Gomez-Aristizabal A, Gandhi R, Mahomed N, Marshall W, Chahal J, Viswanathan S. Quantification of inflammatory cells in knee osteoarthritis synovial fluid and correlation with clinical outcomes Cytotherapy. 20: S64-S65. DOI: 10.1016/J.Jcyt.2018.02.179 |
0.314 |
|
| 2018 |
Waseem S, Bhatt S, Viswanathan S, Audet J. Statistical modeling to optimize the culture of mesenchymal stromal cells Cytotherapy. 20. DOI: 10.1016/J.Jcyt.2018.02.158 |
0.35 |
|
| 2018 |
Bhatt S, Gómez-Aristizábal A, Whiteley J, Rogers I, Viswanathan S. A novel, non-genetic, and scalable proprietary method for enhancing anti-inflammatory, and immunomodulatory properties of mesenchymal stromal cells (MSCs) prior to cryopreservation Cytotherapy. 20: S29. DOI: 10.1016/J.Jcyt.2018.02.073 |
0.37 |
|
| 2018 |
Chaboureau A, Bhatt S, Gomez-Aristizabal A, Chisholm J, Weston A, Fazio A, Kapoor M, Keating A, Ogilvie-Harris D, Mahomed N, Gandhi R, Marshall W, Syed K, Naraghi A, Chahal J, ... Viswanathan S, et al. Potential anti-inflammatory mechanism of action of mesenchymal stromal cells in osteoarthritis patients results in overall improvement in pain and symptoms Cytotherapy. 20: S12. DOI: 10.1016/J.Jcyt.2018.02.019 |
0.322 |
|
| 2017 |
Yannarelli G, Pacienza N, Montanari S, Santa-Cruz D, Viswanathan S, Keating A. OCT4 expression mediates partial cardiomyocyte reprogramming of mesenchymal stromal cells. Plos One. 12: e0189131. PMID 29216265 DOI: 10.1371/Journal.Pone.0189131 |
0.409 |
|
| 2017 |
Williams BA, Law AD, Routy B, denHollander N, Gupta V, Wang XH, Chaboureau A, Viswanathan S, Keating A. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget. 8: 89256-89268. PMID 29179517 DOI: 10.18632/Oncotarget.19204 |
0.372 |
|
| 2017 |
Chisholm J, Bhatt S, Chaboureau A, Viswanathan S. Strategy for an abbreviated in-house qualification of a commercially available Rapid Microbiology Method (RMM) for canadian regulatory approval. Cytotherapy. PMID 29066052 DOI: 10.1016/J.Jcyt.2017.09.004 |
0.354 |
|
| 2017 |
Chisholm J, von Tigerstrom B, Bedford P, Fradette J, Viswanathan S. Workshop to address gaps in regulation of minimally manipulated autologous cell therapies for homologous use in Canada. Cytotherapy. PMID 28964743 DOI: 10.1016/J.Jcyt.2017.08.015 |
0.337 |
|
| 2017 |
Bhatt S, Gómez-Aristizábal A, Viswanathan S. Culture engineered mesenchymal stromal cells with enhanced anti-inflammatory and anti-angiogenic properties are therapeutically attractive for multiple indications Cytotherapy. 19: S196. DOI: 10.1016/J.Jcyt.2017.02.288 |
0.349 |
|
| 2017 |
Read J, Viswanathan S, Bhatt S, Chaboureau A, Gomez-Aristizabal A, Weston A, Fazio A, Ogilvie-Harris D, Kapoor M, Keating A, Mahomed N, Marshall W, Naraghi A, Chahal J. Human autologous mesenchymal stromal cells for the treatment of mid- to late-stage knee osteoarthritis—preliminary results from a first-in-North America phase I/II study Cytotherapy. 19: S24. DOI: 10.1016/J.Jcyt.2017.02.042 |
0.315 |
|
| 2016 |
Gómez-Aristizábal A, Sharma A, Bakooshli MA, Kapoor M, Gilbert PM, Viswanathan S, Gandhi R. Brief Report: Stage-specific differences in secretory profile of mesenchymal stromal cells (MSCs) subjected to early-vs. late-stage OA synovial fluid. Osteoarthritis and Cartilage. PMID 27894935 DOI: 10.1016/J.Joca.2016.11.010 |
0.356 |
|
| 2016 |
Rashedi I, Gomez-Aristizábal A, Wang XH, Viswanathan S, Keating A. TLR3 or TLR4 Activation Enhances MSC-Mediated Treg Induction via Notch Signaling. Stem Cells (Dayton, Ohio). PMID 27571579 DOI: 10.1002/Stem.2485 |
0.34 |
|
| 2016 |
Juneja SC, Viswanathan S, Ganguly M, Veillette C. A Simplified Method for the Aspiration of Bone Marrow from Patients Undergoing Hip and Knee Joint Replacement for Isolating Mesenchymal Stem Cells and In Vitro Chondrogenesis. Bone Marrow Research. 2016: 3152065. PMID 27057356 DOI: 10.1155/2016/3152065 |
0.312 |
|
| 2016 |
Gómez-Aristizábal A, Kim KP, Viswanathan S. A Systematic Study of the Effect of Different Molecular Weights of Hyaluronic Acid on Mesenchymal Stromal Cell-Mediated Immunomodulation. Plos One. 11: e0147868. PMID 26820314 DOI: 10.1371/Journal.Pone.0147868 |
0.348 |
|
| 2016 |
Viswanathan S, Bhatt S, Gómez-Aristizábal A, Chaboureau A, Weston A, Fazio A, Kapoor M, Naraghi A, Mahomed N, Marshall W, Keating A, Ogilvie-Harris D, Chahal J. Human Autologous Mesenchymal Stromal Cells for the Treatment of Mid to Late Stage Knee Osteoarthritis—A Phase I Pilot Study Cytotherapy. 18: S132. DOI: 10.1016/J.Jcyt.2016.03.256 |
0.326 |
|
| 2016 |
Gomez-Aristizabal A, Viswanathan S. Investigating the Role of Reprogramming Monocyte/Macrophages as a Potential Cell-Based Therapy for Osteoarthritis Cytotherapy. 18: S99-S100. DOI: 10.1016/J.Jcyt.2016.03.204 |
0.396 |
|
| 2016 |
Bhatt S, Gómez-Aristizábal A, Viswanathan S. Engineering Culture Methods for Manufacturing High Quality, Increased Potency Mesenchymal Stromal Cells (MSCs) in a Scalable, Economic, and Compliant Manner Cytotherapy. 18: S93. DOI: 10.1016/J.Jcyt.2016.03.183 |
0.343 |
|
| 2015 |
Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MB, LeBlanc K, Martin I, McNiece IK, ... ... Viswanathan S, et al. International society for cellular therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. PMID 26724220 DOI: 10.1016/J.Jcyt.2015.11.008 |
0.405 |
|
| 2015 |
Bubela T, McCabe C, Archibald P, Atkins H, Bradshaw S, Kefalas P, Mujoomdar M, Packer C, Piret J, Raxworthy M, Soares M, Viswanathan S. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regenerative Medicine. 10: 897-911. PMID 26565607 DOI: 10.2217/Rme.15.51 |
0.565 |
|
| 2015 |
Viswanathan S, Bubela T. Current practices and reform proposals for the regulation of advanced medicinal products in Canada. Regenerative Medicine. 10: 647-63. PMID 26237706 DOI: 10.2217/Rme.15.28 |
0.313 |
|
| 2015 |
Wolfstadt JI, Cole BJ, Ogilvie-Harris DJ, Viswanathan S, Chahal J. Current concepts: the role of mesenchymal stem cells in the management of knee osteoarthritis. Sports Health. 7: 38-44. PMID 25553211 DOI: 10.1177/1941738114529727 |
0.41 |
|
| 2015 |
Williams B, Routy B, denHollander N, Wang X, Chaboureau A, Viswanathan S, Keating A. NK-92 Therapy Is Well Tolerated, Has Minimal Toxicity and Shows Efficacy in a Phase I Trial of Patients with Relapsed/Refractory Hematological Malignancies Relapsing after Autologous Stem Cell Transplantation Blood. 126: 4297-4297. DOI: 10.1182/Blood.V126.23.4297.4297 |
0.389 |
|
| 2015 |
Rashedi I, Gomez-Aristizábal A, Wang X, Viswanathan S, Keating A. TLR3 or TLR4 Activation Enhances MSC-Mediated Treg Generation Via Notch Signaling Blood. 126: 3604-3604. DOI: 10.1182/Blood.V126.23.3604.3604 |
0.313 |
|
| 2014 |
Feigal EG, Tsokas K, Viswanathan S, Zhang J, Priest C, Pearce J, Mount N. Proceedings: international regulatory considerations on development pathways for cell therapies. Stem Cells Translational Medicine. 3: 879-87. PMID 25038248 DOI: 10.5966/Sctm.2014-0122 |
0.404 |
|
| 2014 |
Viswanathan S, Keating A, Deans R, Hematti P, Prockop D, Stroncek DF, Stacey G, Weiss DJ, Mason C, Rao MS. Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. Stem Cells and Development. 23: 1157-67. PMID 24422625 DOI: 10.1089/scd.2013.0591 |
0.326 |
|
| 2014 |
Yannarelli G, Tsoporis JN, Desjardins JF, Wang XH, Pourdjabbar A, Viswanathan S, Parker TG, Keating A. Donor mesenchymal stromal cells (MSCs) undergo variable cardiac reprogramming in vivo and predominantly co-express cardiac and stromal determinants after experimental acute myocardial infarction. Stem Cell Reviews. 10: 304-15. PMID 24287730 DOI: 10.1007/S12015-013-9483-Y |
0.374 |
|
| 2014 |
Rupar T, Khan A, Au BC, Tailor C, Rothe M, Bischof D, Sirrs S, Auray-Blais C, Prokopishyn N, O'Hoski P, Huang J, Paul G, Benabid R, Viswanathan S, Morel C, et al. Towards a clinical trial of lentivirus-mediated gene therapy for Fabry disease: In vitro patient cell mobilization and transduction outcomes Clinical Biochemistry. 47: 151. DOI: 10.1016/J.Clinbiochem.2014.07.079 |
0.327 |
|
| 2013 |
Viswanathan S, Rao M, Keating A, Srivastava A. Overcoming challenges to initiating cell therapy clinical trials in rapidly developing countries: India as a model. Stem Cells Translational Medicine. 2: 607-13. PMID 23836804 DOI: 10.5966/Sctm.2013-0019 |
0.446 |
|
| 2013 |
Viswanathan S, Joshi C. Regenerative medicine: challenges and perspectives for successful therapies. Current Topics in Microbiology and Immunology. 367: 101-12. PMID 23208552 DOI: 10.1007/82_2012_290 |
0.309 |
|
| 2012 |
Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells and Development. 21: 2724-52. PMID 22468918 DOI: 10.1089/Scd.2011.0722 |
0.401 |
|
| 2012 |
Swift BE, Williams BA, Kosaka Y, Wang XH, Medin JA, Viswanathan S, Martinez-Lopez J, Keating A. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica. 97: 1020-8. PMID 22271890 DOI: 10.3324/Haematol.2011.054254 |
0.395 |
|
| 2011 |
Viswanathan S, Keating A. Overcoming the challenges of conducting translational research in cell therapy. Frontiers of Medicine. 5: 333-5. PMID 22198744 DOI: 10.1007/S11684-011-0166-2 |
0.372 |
|
| 2005 |
Viswanathan S, Davey RE, Cheng D, Raghu RC, Lauffenburger DA, Zandstra PW. Clonal evolution of stem and differentiated cells can be predicted by integrating cell-intrinsic and -extrinsic parameters. Biotechnology and Applied Biochemistry. 42: 119-31. PMID 15882145 DOI: 10.1042/Ba20040207 |
0.666 |
|
| 2003 |
Viswanathan S, Zandstra PW. Towards predictive models of stem cell fate. Cytotechnology. 41: 75-92. PMID 19002945 DOI: 10.1023/A:1024866504538 |
0.622 |
|
| 2003 |
Viswanathan S, Benatar T, Mileikovsky M, Lauffenburger DA, Nagy A, Zandstra PW. Supplementation-dependent differences in the rates of embryonic stem cell self-renewal, differentiation, and apoptosis. Biotechnology and Bioengineering. 84: 505-17. PMID 14574685 DOI: 10.1002/Bit.10799 |
0.659 |
|
| 2002 |
Viswanathan S, Benatar T, Rose-John S, Lauffenburger DA, Zandstra PW. Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6. Stem Cells (Dayton, Ohio). 20: 119-38. PMID 11897869 DOI: 10.1634/Stemcells.20-2-119 |
0.643 |
|
| Show low-probability matches. |